Nov. 3 - Handicapping the post-election fate of drug price controls | A bet by Bristol Myers pays off, at Amgen's expense
November 03, 2020
In 2020 election, an uncertain fate for drug price controls; Chinese biotech partnered with GSK gets funding boost for coronavirus vaccine; The coronavirus vaccine frontrunners are advancing quickly. Here's where they stand.
Our global infrastructure supports the evolving demands of the clinical trial ecosystem. Store clinical drugs closer to key recruitment areas, reach patients faster, and keep your trials on track. Learn more.
While full data were not disclosed, the trial's outcome signals competition for Amgen's Otezla, which Celgene was forced to divest last year as a result of its acquisition by Bristol Myers.
Three election scenarios could lead to different outcomes for the long-running effort to rein in drug costs. Here's how some analysts think each could play out.
Clover Biopharmaceuticals, one of several China-based groups advancing a coronavirus shot, has now received one of the largest investments to date from the vaccine development alliance group CEPI.
Find out how the 505(b)(2) pathway may offer an attractive alternative for companies looking to differentiate their products and diversify their portfolios. Get the article.
Pfizer could report initial results from its late-stage study any day now, pacing a week or two ahead of Moderna, which could also read out data this month.
BioPharma Dive provides in-depth journalism and insight into the most impactful news and trends shaping biotech and pharma. The newsletter and website cover topics ranging from clinical readouts to FDA approvals, gene therapy to drug pricing and M&A to research partnerships.
BioPharma Dive is a leading industry publication operated by Industry Dive. Our business journalists spark ideas and shape agendas for 10+ million decision makers in the most competitive industries.
This email is optimized for display on mobile phones. BioPharma Dive: Daily Dive is a product of Industry Dive, Inc.. 1575 Eye St NW, 4th Floor, Washington, DC 20005. We value your privacy. We won't share your email address with anyone else without your permission. This message was sent to edwardlorilla1986.acciyo123@blogger.com. You can unsubscribe or switch to a weekly newsletter subscription anytime. See our full privacy policy.
0 Comments